Financial Performance - Operating income for the first nine months was CNY 112,866,865.17, down 44.85% year-on-year[8] - The company's total revenue for the period was CNY 112,866,865.17, a decrease of 44.85% compared to CNY 204,657,293.47 in the same period last year[15] - Total operating revenue for Q3 2014 was CNY 27,292,167.89, a decrease from CNY 64,152,919.02 in the same period last year[28] - Total operating revenue for Q3 2014 was CNY 15,997,680.31, a decrease of 8.8% compared to CNY 17,542,847.67 in Q3 2013[32] - Net profit for Q3 2014 was CNY 4,166,870.98, compared to a net loss of CNY 3,579,112.89 in Q3 2013, indicating a significant turnaround[33] - Basic earnings per share increased to CNY 0.0180 from a loss of CNY 0.0234 in the same period last year[10] - Basic earnings per share for Q3 2014 was CNY 0.0232, compared to a loss of CNY 0.0314 per share in Q3 2013[33] Cash Flow - Net cash flow from operating activities was negative CNY 4,474,331.33, a decrease of 112.93% compared to the same period last year[8] - The cash flow from operating activities showed a net outflow of CNY 4,474,331.33, a significant decrease of 112.93% compared to a net inflow of CNY 34,611,889.01 in the previous year[16] - Cash flow from operating activities for the first nine months of 2014 was CNY -4,474,331.33, a decline from CNY 34,611,889.01 in the same period of 2013[37] - Total cash inflow from operating activities was 38,077,811.17 RMB, down 62.3% from 101,034,710.61 RMB year-on-year[41] - Cash outflow from operating activities totaled 38,707,462.86 RMB, a decrease of 60.4% compared to 97,583,479.99 RMB in the previous year[41] - Net cash flow from financing activities was 1,602,087.00 RMB, a significant improvement from -11,314,914.63 RMB in the previous year[42] Assets and Liabilities - Total assets decreased by 10.74% to CNY 289,712,142.11 compared to the end of the previous year[8] - The company reported a decrease in accounts receivable to CNY 35,225,579.56 from CNY 42,864,973.42, a reduction of 17.56%[19] - The company’s inventory decreased to CNY 53,707,966.14 from CNY 84,875,285.43, a reduction of 36.73%[19] - Total assets as of September 30, 2014, amounted to CNY 178,125,490.02, a decrease from CNY 186,345,476.51 at the beginning of the year[24][25] - Total liabilities as of September 30, 2014, were CNY 121,451,646.43, an increase from CNY 113,535,443.27 at the beginning of the year[25] - Shareholders' equity decreased to CNY 56,673,843.59 from CNY 72,810,033.24 at the beginning of the year[25] Government Subsidies - Government subsidies recognized in the current period amounted to CNY 2,217,574.16, contributing to the net profit[10] - The company reported a total of CNY 6,505,310.57 in government subsidies for the year-to-date[10] Shareholder Information - The total number of shareholders reached 10,242 by the end of the reporting period[11] - The top ten shareholders held a combined 56.56% of the total shares, with the largest shareholder holding 9,567,950 shares, representing 7.86%[12] Cost Management - Operating costs amounted to CNY 69,570,525.95, reflecting a decline of 54.15% from CNY 151,731,306.62 year-on-year[15] - The company reported a total operating cost of CNY 6,161,277.88 for Q3 2014, down from CNY 8,890,133.54 in Q3 2013, reflecting improved cost management[32] - The company incurred a financial expense of CNY 1,337,840.23 in Q3 2014, slightly down from CNY 1,479,699.04 in Q3 2013[32] Investment Activities - The company’s investment income decreased by 40.42% to CNY 2,842,082.40, down from CNY 4,770,448.91 year-on-year[15] - Investment activities resulted in a net cash outflow of CNY -23,623,574.99 for the first nine months of 2014, compared to a net inflow of CNY 2,957,524.41 in the same period of 2013[38] - Investment cash inflow amounted to 12,788,350.40 RMB, an increase of 84.5% from 6,908,840.91 RMB year-on-year[42] - Net cash flow from investment activities was -1,264,307.80 RMB, compared to 3,775,924.31 in the same period last year, indicating a decline of 133.5%[42] Other Information - The company has not disclosed any new product developments or market expansion strategies in this report[8] - The company reported a significant decrease in cash received from sales of goods and services, totaling 33,901,844.13 RMB, down 27.6% from 46,835,494.68 RMB year-on-year[41]
*ST目药(600671) - 2014 Q3 - 季度财报